Combination drug

A combination drug is a medication consisting of at least two drugs as active ingredients combined in a single dosage form, usually in a fixed-dose combination, where each active component is at an exactified, standardized dose. Fixed-dose combinations are mass produced and mass marketed, intended to serve as a near universal treatment for a large patient population with diverse medical histories, conditions, predisposition thereof, and treatment requirements. A polypill is a pharmacy or capsule containing four or more active ingredients, often needing to be compounded at a specialized pharmacy in order to satisfy a patient's medical prescription (e.g. dosage form, dose, and/or mechanism/action of release ias part of the individual's overall care and personalized treatment plan. Polypills encompass approved prescription drugs, over the counter drugs, as well as nutritional supplements, amino acids, vitamins, minerals, and hormones as necessary.

Fixed-dose combination drugs were initially developed to target a single disease, as with antiretroviral FDCs indicated for treating AIDS and HIV. Over time, the concept of combination drugs has come to include reducing pill burden for patients, thereby encouraging patient compliance, and generally simplifying treatment plan with one product containing easily accessible (often available over the counter without a prescription requirement), relatively affordable (often generic drugs) ingredients with established therapeutic efficacy and a broad capacity for treating a variety of symptoms and conditions, thus ensuring maximum appeal to a majority of patients amongst a large population with varying needs.

Current prescription combination drugs

The combination drugs listed below are typically available by prescription only, but specific circumstances regarding a given combination's legal accessibility, or any specific regulation pertinent to ingredient quality, quantities, production standards, sourcing, etc. will vary by jurisdictions, and include:

Combination drugs accessible Over-the-counter (OTC)

Fixed-dose combination drugs for sale over the counter (OTC) exist around the world, constituting doses that are tolerable to the mainstream consumer population. In the United States, items containing ephedrine, pseudoephedrine, or phenylpropanolamine can be purchased without a prescription, albeit under oversight and at the pharmacy, per U.S. Federal drug law, namely the Combat Methamphetamine Epidemic Act of 2005.

Fixed-dose combination drugs for sale over the counter internationally, including medicine indicated for various purposes:

Combination drugs under development, not yet approved for medical use

Combinations drugs for veterinary use

Combination drugs no longer widely available

Medical use and justification of discontinued combination drugs

Most of the combination drugs which have been discontinued since the twentieth century were simultaneously indicated and utilized for treatment of various conditions, with medical use justified as part of a multifaceted, comprehensive approach to patient health care and medical treatment. Central nervous system stimulants (colloquially called "uppers") were used as appetite suppressants, antidepressants, and wakefulness-promoting agents, and further effects include increased mental alertness and concentration/focus, as well as physical energy and motivation. The addition of a central nervous system depressant mitigated the stimulant's adverse effects without eliminating therapeutic benefits. In most cases, the "upper" component of these combination drugs was a salt, or mixed salts, of racemic amphetamine, dextroamphetamine, or methamphetamine, while the "downer" was typically one or more barbiturates (most commonly amobarbital, phenobarbital, pentobarbital, and/or secobarbital) or similar GABAergic, non-barbiturate tranquilizers or sedatives, frequently meprobamate or methaqualone, respectively, which provided anxiolytic, muscle relaxant, and hypnotic effects. Upper and downer combination drugs were often capable of substituting for Monoamine Oxidase Inhibitors (MAOIs) in patients with treatment-resistant depression where MAOIs are indicated, but where MAOI-related dietary restrictions would impact patient's life.

Combination drugs offer the advantage over polypharmacy by decreasing patients' pill burden. Overall, giving patients the ability to take control and alleviate symptoms, and potentially treat or cure multiple conditions by consuming all of their medical treatments efficacious treatment options by the ingestion of a single pill, which consistently improves patient medication compliance by reducing their pill burden. The American Association of Orthodontists asserts that fixed-dose combinations "limit clinicians' ability to customize dosing regimens."

Scientists formulating combination drugs face challenges in the development stages of multi-drug formulations such as compatibility issues among active ingredients and excipients affecting solubility and dissolution For prescribers, if one constituent of the combination is contraindicated for a patient, the product cannot be prescribed.

Illicit streets as de facto drug combinations

Illicit stimulants

Illicit combination drugs are often formulated as a powder, paste, or counterfeit "pressed" pills intended to resemble their pharmaceutical-grade counterparts. Since 2018, ABC News of Houston reports that product described as "powder cocaine" originating from a clandestine laboratory are increasingly analyzed and found to contain other stimulants, in order to mimic cocaine's effects in a cost-effective, deceptive manner; many of the batches analyzed did not contain any cocaine or coca alkaloids whatsoever; instead, they were blends of various designer drugs, research chemicals, methamphetamine, and/or various amphetamines, derivatives, analogues; MDMA, caffeine powder, ephedrine or pseudoephedrine; levamisole, a flesh-eating veterinary antibiotic

Limitations of currently-available combinations

The limitations of combination formulations currently available for treating a widely-inclusive collection of symptoms such as Tourette's is highlighted by there not being a polypill or any combination formula period approved for treating the condition. Medication available, and sometimes used in the context of polypharmacy involves various individual medicines for treating tics and/or generalized anxiety or social anxiety disorder and/or obsessive-compulsive anxieties with use of individual benzodiazepines or SSRIs for the former two conditions, and fluvoxamine or clomipramine first-line treatments for OCD and related disorders, such as hoarding or compulsive decluttering. But, where Attention-Deficit Hyperactivity Disorder, depression, or insomnia become a primary concern to the patient, it is only through polypharmacy (in this case, adding another antidepressant or a "booster, alongside a hypnotic soporific agent, and/or psychostimulants to both treat ADHD and counteract the sleep inertia, grogginess or hangover caused by the other evening medications).

Tourette syndrome is a neurological tic disorder whose only FDA-approved treatment is the neuroleptic pimozide, a drug only used for tics due Tourette's disorder; every other treatment is an off-label use. While Tourette's is typically identified by chronic motor and vocal tics–"semi-voluntary" movements and noises made in response to a "premonitory urge," an internal buildup of compulsive tension that can only be temporarily upon performing/making the motion/sound demanded by compulsion. Tourette's, however, is an all-encompassing umbrella term that includes not just chronic physical and phonic tics, but also presents with such comorbid symptoms as anxiety (often OCD, social anxiety, schizoid personality, avoidant personality disorder, or generalized anxiety), ADHD, insomnia, depression, and traits of high-functioning autism formerly called Asperger syndrome.

Illicit depressants and opiates

Due to the crackdown of pill mills between 2007-2012, the opioid epidemic now includes preparations declared to be "heroin" or "pressed" replica pills of hydrocodone (sold Norco or LorTab); oxycodone (sold as Percocet), yet are rarely pure in their ingredient compositions. Cutting agents have grown in proportion to the overall composition of these products, such that "heroin" has been cut and mixed with central nervous system depressants including major tranquilizers such as quetiapine; muscle relaxants like carisoprodol or cyclobenzaprine; first-generation antihistamines like diphenhydramine or hydroxyzine); and benzodiazepine derivative and analogue research chemicals, including gidazepam, pinazepam, clobromazolam, etizolam). Since 2020, there has been a noticeable rise amongst active ingredients in opioid combinations containing fentanyl (more potent than heroin), and increasingly, carfentanil (an elephant and rhinoceros tranquilizer more potent than fentanyl).

Since 2023, worldwide samples of illicit combinations featuring opioids have contained the most lethal known substance to date: those belong to the nitazene chemical class. have been found in these opioid samples– all of which mimic the muscle relaxant, anxiolytic, and analgesic properties of pharmaceutical-grade opioid medications. U.S. Attorney General has indicated interested in federally regulating the relative mild veterinary sedative xylazine, which is currently available by prescription only, as a federally-controlled Schedule III controlled substance per the Controlled Substances Act, a direct response to its implication in overdose deaths featured in products alongside fentanyl and other power central nervous system depressants; xylazine is currently a controlled substance at the state level in Michigan and New York.

See also

Notes

References

Uses material from the Wikipedia article Combination drug, released under the CC BY-SA 4.0 license.